|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 22.81 CNY | -0.31% |
|
-3.35% | +33.31% |
| 08-12 | Henan Lingrui Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2024 | CI |
| 05-13 | Lingrui Pharma Gets Green Light to Market Type 2 Diabetes Drug | MT |
Share class: Henan Lingrui Pharmaceutical Co., Ltd.
| Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
|---|---|---|---|---|---|
| Stock A | 1 | 571,068,496 | 437,385,577 ( 76.59 %) | 3,953,010 ( 0.6922 %) | 76.59 % |
Major shareholders: Henan Lingrui Pharmaceutical Co., Ltd.
| Name | Equities | % | Valuation |
|---|---|---|---|
Henan Lingrui Group Co., Ltd.
20.77
%
| 121,817,898 | 20.77 % | 401 M ¥ |
GF Fund Management Co., Ltd.
5.962
%
| 34,962,760 | 5.962 % | 115 M ¥ |
First Seafront Fund Management Co., Ltd.
3.701
%
| 21,702,257 | 3.701 % | 72 M ¥ |
Henan Lingrui Pharmaceutical Co., Ltd.
3.278
%
| 19,226,445 | 3.278 % | 63 M ¥ |
Wei Zheng Xiong
2.272
%
| 13,324,200 | 2.272 % | 44 M ¥ |
Zhong Ou Asset Management Co., Ltd
1.921
%
| 11,264,817 | 1.921 % | 37 M ¥ |
Basic Pension Insurance Fund 1303 Combination
1.199
%
| 7,030,284 | 1.199 % | 23 M ¥ |
Fullgoal Fund Management Co., Ltd.
1.079
%
| 6,330,644 | 1.079 % | 21 M ¥ |
China Southern Asset Management Co., Ltd.
1.012
%
| 5,936,287 | 1.012 % | 20 M ¥ |
Taikang Asset Management Co. Ltd.
0.8491
%
| 4,979,549 | 0.8491 % | 16 M ¥ |
| ░░░░░░░░░░░░░░░░░░░░░░░ | ░ ░░░ | ░░░░% | ░░ |
| ░░░░░░░░░░░░░░░░░░░░░░░░░ | ░ ░░░ | ░░░░% | ░░ |
| ░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░ | ░ ░░░ | ░░░░% | ░░ |
| ░░░░░░░░░░░░░░░░ | ░ ░░░ | ░░░░% | ░░ |
| ░░░░░░░░░░░░░░░░░░░░░░░░░░░ | ░ ░░░ | ░░░░% | ░░ |
| ░░░░░░░░░░░░░░░░░░░░░░░░░░ | ░ ░░░ | ░░░░% | ░░ |
| ░░░░░░░░░░░░░░░░░░░░░░░ | ░ ░░░ | ░░░░% | ░░ |
| ░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░ | ░ ░░░ | ░░░░% | ░░ |
| ░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░ | ░ ░░░ | ░░░░% | ░░ |
| ░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░ | ░ ░░░ | ░░░░% | ░░ |
| ░░░░░░░░░░░░░░░░░░░░░░░░░░░░░ | ░ ░░░ | ░░░░% | ░░ |
| ░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░ | ░ ░░░ | ░░░░% | ░░ |
| ░░░░░░░░░░░░░░░░░░░ | ░ ░░░ | ░░░░% | ░░ |
| ░░░░░░░░░░░░░░░░░░░░ | ░ ░░░ | ░░░░% | ░░ |
| ░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░ | ░ ░░░ | ░░░░% | ░░ |
| Name | Equities | % | Valuation |
|---|---|---|---|
Xi Zhen Wu
2.806
%
| 228,000 | 2.806 % | 751 401 ¥ |
Breakdown by shareholder type
| Other | 22.53% |
| Institutional | 19.71% |
| Henan Lingrui Pharmaceutical Co., Ltd. | 3.28% |
| Individuals | 3.00% |
| Unknown | 51.48% |
Based on 1000 largest holdings
Geographical origin of shareholders
| China | 45.52% |
| Individuals | 3.00% |
Based on 1000 largest holdings
Employees
2,530
Sector
Pharmaceuticals
Calendar
2024-10-24
- Q3 2024 Earnings Release (Projected)
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition